NasdaqCM - Nasdaq Real Time Price USD

BriaCell Therapeutics Corp. (BCTX)

5.35

+1.16

+(27.68%)

At close: April 22 at 4:00:01 PM EDT

4.40

-0.95

(-17.76%)

Pre-Market: 4:00:44 AM EDT

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

Over 75 patients enrolled in BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer (MBC)54 clinical sites across 15 states currently enrolling patients including Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer and Bood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center PHILADEL

GlobeNewswire 21 hours ago

BCTX
+27.68%
BCTXW
BriaCell Therapeutics Up 7% as It Reports Latest Survival Data From Phase 2 Breast Cancer Study

BriaCell Therapeutics (BCT.TO) up near 7% on last look, on Wednesday reported new positive survival

PREMIUM
MT Newswires 6 days ago

BCTXW
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) metastatic breast cancer markedly exceeds historical data of 14.4 months in TRODELVY® (sacituzumab govitecan-hziy) in similar heavily pre-treated patientsSurvival data in triple negative breast cancer patients treated with the BriaCell regimen was comparable to TRODELVY® No Bria-IMT related discontinuations reported to date PHILADELPHIA and VANCOUVER, British Columbia, April 16, 2025 (GLOBE

GlobeNewswire 6 days ago

BCTX
+27.68%
BCTXW
BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpointHighly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer target for drugs both effecting cancer cells and blocking immune checkpoint activityBriaPro expects to advance anti-B7-H3 antibodies into development of proprietary antibody-drug conjugates, T cell engagers, and targeted immune checkpoint inhibitors with potential applications in multiple cancer indicatio

GlobeNewswire 12 days ago

BCTX
+27.68%
BCTXW
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chic

GlobeNewswire 27 days ago

BCTX
+27.68%
BCTXW
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer

The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration (FDA) PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a cl

GlobeNewswire last month

BCTX
+27.68%
BCTXW
BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for BRIACELL THERAP (BCTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks 2 months ago

BCTXW
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2024 held on February 5, 2025 (the “Meeting”). A total of 36.26% of the Compan

GlobeNewswire 2 months ago

BCTX
+27.68%
BCTXW
BriaCell Therapeutics Announces Closing of Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. The Company received gross proceeds from the offering, before deductin

GlobeNewswire 2 months ago

BCTX
+27.68%
BCTXW
BRIACELL THERAP (BCTX) Upgraded to Buy: What Does It Mean for the Stock?

BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 2 months ago

BCTXW
BriaCell Therapeutics Announces Pricing of Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 762,500 common shares at a public offering price of $4.00 per share. Total gross proceeds from the offering, before deducting placement agent fees and other offer

GlobeNewswire 2 months ago

BCTX
+27.68%
BCTXW
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced that it intends to offer to sell common shares in a best-efforts public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, o

GlobeNewswire 2 months ago

BCTX
+27.68%
BCTXW
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapyNo toxicity related to the treatment; Patient remains on studyUnprecedented result in first patient dosed supports Bria-OTS™ personalized immunotherapy approachOngoing Phase 1/2a dose escalation study to evaluate Bria-OTS™, BriaCell's personalized off-the-shelf immunotherapy in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE N

GlobeNewswire 2 months ago

BCTX
+27.68%
BCTXW
BriaCell Announces Completion of 15:1 Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announces that on January 24, 2025 (the “Effective Date”), the Company completed a share consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) pos

GlobeNewswire 2 months ago

BCTX
+27.68%
BCTXW
BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Co

GlobeNewswire 3 months ago

BCTX
+27.68%
BCTXW
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company’s Annual General Meeting of Shareholders (the “Meeting”), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wedn

GlobeNewswire 3 months ago

BCTX
+27.68%
BCTXW
Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m

Insiders who bought US$5.52m worth of BriaCell Therapeutics Corp.'s ( TSE:BCT ) stock at an average buy price of...

Simply Wall St. 4 months ago

BCTX
+27.68%
BCTXW
BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaPro Therapeutics Corp. (“BriaPro” or the “Company”), a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-rel

GlobeNewswire 4 months ago

BCTX
+27.68%
BCTXW
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials

GlobeNewswire 4 months ago

BCTX
+27.68%
BCTXW
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associa

GlobeNewswire 4 months ago

BCTX
+27.68%
BCTXW

Performance Overview

Return	BCTX	S&P/TSX Composite index (^GSPTSE)
YTD	+838.60%	-1.28%
1-Year	+143.18%	+11.13%
3-Year	-28.19%	+14.72%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BriaCell Therapeutics Corp. (BCTX)

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)

BriaCell Therapeutics Up 7% as It Reports Latest Survival Data From Phase 2 Breast Cancer Study

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer

BriaCell's Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer

BRIACELL THERAP (BCTX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaCell Therapeutics Announces Closing of Public Offering

BRIACELL THERAP (BCTX) Upgraded to Buy: What Does It Mean for the Stock?

BriaCell Therapeutics Announces Pricing of Public Offering

BriaCell Therapeutics Announces Proposed Public Offering of Common Shares

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

BriaCell Announces Completion of 15:1 Share Consolidation

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m

BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering

Performance Overview